Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Agios Pharmaceuticals (AGIO) Net Income towards Common Stockholders: 2012-2025

Historic Net Income towards Common Stockholders for Agios Pharmaceuticals (AGIO) over the last 14 years, with Sep 2025 value amounting to -$103.4 million.

  • Agios Pharmaceuticals' Net Income towards Common Stockholders fell 110.91% to -$103.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$403.0 million, marking a year-over-year decrease of 160.06%. This contributed to the annual value of $673.7 million for FY2024, which is 291.35% up from last year.
  • Latest data reveals that Agios Pharmaceuticals reported Net Income towards Common Stockholders of -$103.4 million as of Q3 2025, which was up 8.09% from -$112.5 million recorded in Q2 2025.
  • Agios Pharmaceuticals' 5-year Net Income towards Common Stockholders high stood at $2.0 billion for Q1 2021, and its period low was -$112.5 million during Q2 2025.
  • For the 3-year period, Agios Pharmaceuticals' Net Income towards Common Stockholders averaged around $796,545, with its median value being -$91.3 million (2023).
  • As far as peak fluctuations go, Agios Pharmaceuticals' Net Income towards Common Stockholders surged by 4,382.87% in 2021, and later plummeted by 2,696.82% in 2022.
  • Over the past 5 years, Agios Pharmaceuticals' Net Income towards Common Stockholders (Quarterly) stood at $4.0 million in 2021, then tumbled by 2,442.28% to -$92.7 million in 2022, then dropped by 3.51% to -$95.9 million in 2023, then decreased by 0.61% to -$96.5 million in 2024, then slumped by 110.91% to -$103.4 million in 2025.
  • Its Net Income towards Common Stockholders stands at -$103.4 million for Q3 2025, versus -$112.5 million for Q2 2025 and -$90.5 million for Q1 2025.